Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Aethlon Medical (Nasdaq: AEMD), a clinical-stage medical device company, will release its fiscal Q1 2025 financial results on August 13, 2025 at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET.
The company's main product, the Hemopurifier®, is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation. The device holds FDA Breakthrough Device Designation for treating advanced cancer patients unresponsive to standard therapy and life-threatening viruses without approved treatments.
Aethlon Medical (Nasdaq: AEMD) announced positive safety review results from the independent Data Safety Monitoring Board (DSMB) for its ongoing clinical trial AEMD-2022-06 of the Aethlon Hemopurifier®. The trial is evaluating the device's safety and optimal dosing in cancer patients with stable or progressive disease while on Pembrolizumab or Nivolumab treatment.
The DSMB reviewed data from the initial three-patient cohort, who each received a single 4-hour Hemopurifier treatment, finding no safety concerns or serious adverse events. The board recommended advancing to Cohort 2, where participants will receive two Hemopurifier treatments over one week. The trial aims to enroll 9-18 patients across three Australian clinical sites.
The study targets patients among the 60-70% who don't respond well to anti-PD-1 immunotherapy, with findings intended to inform future Premarket Approval studies.
Aethlon Medical (Nasdaq: AEMD) reported financial results for Q4 FY2025 and provided corporate updates. Key highlights include treatment of three patients in the Hemopurifier® cancer trial in Australia, regulatory approval in India, and significant operational cost reductions. The company's cash balance stood at $5.5 million as of March 31, 2025.
Operating expenses decreased by 26% to $9.3 million from $12.6 million year-over-year. Preclinical data showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment. The company is expanding research into Long COVID applications through collaboration with UCSF, addressing a market affecting 44-48 million people in the US.
Aethlon Medical (NASDAQ: AEMD) has published preclinical study results in Transplant Immunology demonstrating new potential applications for its Hemopurifier® blood filtration system in organ transplantation. The study, published February 28, 2025, shows the device's effectiveness in removing harmful extracellular vesicles (EVs) and microRNAs from renal perfusates of discarded donor kidneys.
The research indicates significant reductions in EVs and microRNAs linked to renal dysfunction, suggesting potential benefits for kidney transplant outcomes. This expands the Hemopurifier's therapeutic potential beyond its current applications in virology and oncology, presenting what the company calls a "pipeline within a device."
While the company's primary focus remains on Australian and India Oncology trials, these findings suggest the technology could potentially be integrated with existing organ preservation systems, though further evaluation and clinical trials would be necessary.
Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing products for cancer and life-threatening infectious diseases, will present at the Emerging Growth Conference on February 19, 2025. The company's CEO, James Frakes, will deliver a 30-minute presentation starting at 11:25 AM Eastern time.
This interactive online event offers shareholders and the investment community the opportunity to engage directly with Mr. Frakes in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session.
For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel. Registration is required through the provided webcast link to attend and receive updates.
Aethlon Medical (NASDAQ: AEMD) reported its fiscal Q3 2024 results and key developments. The company achieved a significant milestone with the first patient treated in their Hemopurifier® cancer trial in Australia on January 29, 2025. The treatment was completed successfully with no device-related complications.
The company implemented protocol modifications to improve trial efficiency, including changes to patient enrollment criteria and broadening eligibility requirements. Two clinical sites are currently active in Australia, with a third site expected to activate in February 2025.
Financial highlights include a cash balance of $4.8 million as of December 31, 2024. Operating expenses decreased by 50% to $1.8 million compared to $3.6 million in the same quarter last year, primarily due to reduced payroll expenses, professional fees, and general administrative costs. Net loss decreased to $1.8 million from $3.5 million in the prior year period.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
